At MedFIT 2025, held on December 2–3 in Strasbourg (with an additional digital day on December 8), one message came through clearly:
European healthtech is done experimenting. The focus has shifted to execution, compliance, and commercial reality.
With more than 900 founders, investors, corporates, and researchers from over 35 countries gathered in one place, the event saw various patterns emerge.
This year’s edition brought together MedTech, diagnostics, biotech, and digital health stakeholders to collaborate over meetings, pitches, exhibitions, and tightly focused conference tracks and move medtech conversations forward.
But beyond the numbers and sessions, MedFIT 2025 offered a useful snapshot of where the ecosystem is heading next.
Inside MedFIT: Less hype, more structure
MedFIT has always positioned itself as a business-first partnering event rather than a demo showcase. And that identity was especially visible this year.
With over 1,800 one-on-one meetings, the emphasis was clearly on:
- Deal-making over visibility
- Collaboration over competition
- Long-term partnerships over quick pilots
This wasn’t about chasing trends. It was about making innovation work inside a heavily regulated, cost-sensitive European healthcare system.
Three tracks, one overarching theme: Viability
The conference program ran across three tracks—collaboration, financing, and digital health—but the conversations consistently circled back to a single question:
Can this actually scale in Europe?
1. Collaboration isn’t optional anymore
Universities, technology transfer offices, and research institutions made up nearly 20% of participants, reinforcing how central academia remains to Europe’s MedTech and biotech pipelines.
But the tone around collaboration was refreshingly honest. Panelists repeatedly warned that:
- Many startup–corporate partnerships fail due to vague expectations
- Licensing discussions often break down over poorly defined milestones.
- Legal and negotiation expertise is still underestimated by early-stage founders.
The takeaway was to collaborate better. Invest in good legal and negotiation support early to maintain long-term partnerships.
Sustainability also surfaced as a non-negotiable aspect. With European regulations tightening, environmentally conscious device design is quickly becoming table stakes rather than a branding exercise.
2. Funding has become more selective
Despite ongoing caution in European venture markets, MedFIT 2025 highlighted that capital is still flowing, but only to companies with focus.
Across funding panels and CEO discussions, investors consistently looked for:
- Clear clinical relevance
- Evidence-backed value propositions
- Realistic paths to revenue
Hardware wasn’t dismissed, but “AI-powered” alone no longer moves the needle. Founders were cautioned against adding AI as a buzzword without any solid value in convergence projects that combine MedTech, Biotech, and digital health.
One recurring insight from fundraising veterans:
Raising capital now takes longer, relies more on trust, and demands brutal honesty about risk.
3. Digital health is growing up
Digital health sessions reflected a more mature phase of the sector. Instead of broad “transformation” narratives, discussions focused on:
- Clinician adoption
- Narrow, well-defined use cases
- Market-by-market entry strategies
Panels on the EU AI Act were particularly pragmatic. The advice was to:
Design for compliance from day one.
Founders were encouraged to build transparency, documentation, and risk management into their products early. Because retrofitting compliance later is costly and often fatal to momentum.
MEDigIT and BioFIT: Two signals of where innovation is moving
Two parallel programs stood out for different reasons.
MEDigIT, Europe’s digital health innovation forum, highlighted the sector’s pivot toward B2C viability, AI governance, and reimbursement-aware design. Rather than chasing scale prematurely, startups focused on proof, partnerships, and regulatory readiness.
At the MedFIT event, it helped accelerate funding, address regulatory changes, build partnerships for research and development, and had pitch sessions to show innovations.
BioFIT, meanwhile, reinforced the strength of Europe’s academia–industry pipeline. Early-stage technology transfer, seed funding, and structured collaboration were the central themes, especially for biotech and diagnostics founders navigating long development cycles.
Together, they underscored that the lines between MedTech, biotech, and digital health are blurring fast.
Innovation on display
The event had more than 100 exhibitors with over 36 innovation pitches that attracted investors and industry leaders. It was built on the success of past events that generated 550+ deals, including 40% commercial collaborations and 25% R&D partnerships.
Some innovations that drew attention:
- Innobiochips’ Omnys platform showcased advances in blood transfusion diagnostics, attracting strong interest from industry professionals, and positioned itself as a leader in in-vitro diagnostics.
- 37 DEGRES highlighted its thermal male contraceptive. A rare example of non-hormonal contraception innovation aimed at men.
- Component suppliers like CGR International emphasized how progress in photonics and precision components continues to quietly power breakthroughs across imaging and minimally invasive devices.
These weren’t flashy launches; they were practical solutions aimed at real clinical and manufacturing challenges.
Startups, recognition, and what investors are watching
The startup slams reinforced MedFIT’s focus on substance over spectacle.
- Soundsafe Care (MedFIT) and BOARD4CARE (MEDigIT) were recognized as Europe’s most innovative MedTech and digital health startups.
- Collaboration and licensing awards went to Amsterdam UMC and miRoncol Health, highlighting the value placed on translational partnerships.
- A separate PUI Lille Innovation Contest awards ceremony allocated €5,000–€50,000 worth of support and expertise to several regional innovation projects. It emphasized MedFIT’s role in strengthening local ecosystems alongside pan-European ambition.
The bigger picture: What MedFIT 2025 revealed
More than anything, MedFIT 2025 reflected a European healthtech ecosystem that is resetting its priorities.
This is an industry:
- Moving from vision to validation
- Treating regulation as a design input
- Valuing collaboration as a growth strategy
- Focusing on sustainability
While global investment trends will shape what scales next, MedFIT showed that execution discipline will decide who survives long enough to benefit.
More about MedFIT
MedFIT is an annual European event for business conventions and partnerships that brings together international stakeholders for early-stage Research and Development projects, collaborative ventures, and market access for new technologies.
This event is important for the MedTech Industry as it builds collaborations, helps start-ups receive funding, speeds up market access, sources innovations, and helps experts exchange knowledge.
